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Open access una b s t r a c t
Recent development of personal sequencers for extensive mutation analysis and bead array technology
for comprehensive DNA methylation analysis have made it possible to obtain integrated pictures of
genetic and epigenetic alterations on the same set of cancer samples. Here, we aimed to establish such
pictures of gastric cancers (GCs). Comprehensive methylation analysis of 30 GCs revealed that the num-
ber of aberrantly methylated genes was highly variable among individual GCs. Extensive mutation anal-
ysis of 55 known cancer-related genes revealed that 19 of the 30 GCs had 24 somatic mutations of eight
different genes (CDH1, CTNNB1, ERBB2, KRAS, MLH1, PIK3CA, SMARCB1, and TP53). Integration of informa-
tion on the genetic and epigenetic alterations revealed that the GCs with the CpG island methylator phe-
notype (CIMP) tended to have mutations of oncogenes, CTNNB1, ERBB2, KRAS, and PIK3CA. This is one of
the ﬁrst studies in which both genetic and epigenetic alterations were extensively analyzed in the same
set of samples. It was also demonstrated for the ﬁrst time in GCs that the CIMP was associated with onco-
gene mutations.
 2012 Elsevier Ireland Ltd. Open access under  CC BY-NC-ND license.1. Introduction
Both genetic and epigenetic alterations are important for hu-
man carcinogenesis [1,2]. Genetic alterations are responsible for
activation of oncogenes and inactivation of tumor-suppressor
genes [2]. In human gastric cancers (GCs), oncogenes activated
by mutations include CTNNB1 (b-catenin), ERBB2, and PIK3CA [3–
10], and tumor-suppressor genes inactivated by mutations include
CDH1 (E-cadherin), CDKN2A (p16), TP53, and ARID1A [11,12]. Even
by whole exome sequencing of GCs, the vast majority of driver
genes identiﬁed were known cancer-related genes, and novel
genes identiﬁed, such as ARID1A and FAT4, had only low incidencesH. pylori, Helicobacter pylori;
s, Epstein–Barr virus; TSS,
c Mutations In Cancer.
der  CC BY-NC-ND license.of mutations [11,12]. This indicates that extensive mutation anal-
ysis of a large number of known cancer-related genes can provide
an overall picture of a cancer sample, and this is now possible with
high speed and low cost by using next-generation personal
sequencers [13,14].
Epigenetic alterations, namely aberrant DNA methylation of
promoter CpG islands (CGIs), are also responsible for inactivation
of various tumor-suppressor genes [1]. DNA methylation statuses
of the entire genome can be now comprehensively analyzed using
microarray technologies, and bead array technology is especially
useful for its quantitative measurement [15]. In GCs, tumor-
suppressor genes inactivated by promoter methylation include
CDH1, CDKN2A, FHL1, LOX, MLH1, and SFRP family genes (SFRP1,
SFRP2, and SFRP5) [16–21]. These tumor-suppressor genes are
more frequently inactivated by aberrant methylation than by ge-
netic alterations in GCs [22]. In addition, aberrant methylation is
induced in gastric mucosae by Helicobacter pylori (H. pylori)
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[25]. The frequent inactivation of tumor-suppressor genes by aber-
rant methylation and the deep involvement of H. pylori infection in
its induction indicate the importance of epigenetic alterations in
GCs.
Not only in GCs but also in other types of cancers, a subgroup of
cancers is known to have frequent aberrant DNA methylation of
CGIs, referred to as the CpG island methylator phenotype (CIMP).
The CIMP was ﬁrst described in colorectal cancers [26], and is asso-
ciated with unique clinicopathological features. For example, the
CIMP is associated with poor prognosis in colorectal cancers, lung
cancers, and neuroblastomas [27–29]. In contrast, depending on
the number and set of genes used for the determination of the
CIMP status, the CIMP can be associated with either poor or good
prognosis in GCs [30–33]. The CIMP in speciﬁc cancers is associated
with genetic alterations, such as mutations of BRAF, KRAS, and
PIK3CA in colorectal cancers [34–37], and ampliﬁcation of ERBB2
in breast cancers [38]. In contrast, little is known on a speciﬁc asso-
ciation between the CIMP and genetic alterations in GCs.
In this study, we aimed to establish integrated pictures of ge-
netic and epigenetic alterations of GCs. To this end, we conducted
comprehensive analysis of DNA methylation statuses using bead
array technology, and extensive analysis of mutations of 55 known
cancer-related genes using a next-generation personal sequencer.
2. Materials and methods
2.1. Samples
Thirty GC samples were obtained from patients who underwent gastrectomy
with informed consents. Three normal gastric mucosae samples were obtained
endoscopically from healthy volunteers without H. pylori infection with informed
consents. The study was approved by the Institutional Review Boards. The samples
were stored in RNAlater (Life Technologies, Carlsbad, CA) at 80 C until the extrac-
tion of genomic DNA (GC samples and normal gastric mucosae samples) and RNA
(normal gastric mucosae samples). Clinical information of the 30 GCs is shown in
Supplementary Table 1. The status of Epstein–Barr (EB) virus infection was evalu-
ated by PCR using primers speciﬁc to genomic DNA of EB virus (forward, CGGTAT-
TATGTTTTTGGTATGTGTA; reverse, ATAACAACAACGTCATAAAAACCAC), and no
infection was present in the 30 GCs.
Genomic DNA was extracted from GC and normal gastric mucosae samples by
the phenol/chloroform method, and was quantiﬁed by using a Quant-iT PicoGreen
dsDNA Assay Kit (Life Technologies). Total RNA was isolated using ISOGEN (Nippon
Gene, Tokyo, Japan).
2.2. Analysis of DNA methylation
Analysis of DNA methylation was performed using an Inﬁnium HumanMethyla-
tion450 BeadChip array, which covered 482,421 CpG sites (Illumina, San Diego, CA)
as described previously [39]. CpG sites with low signals (signal <500, 0.19–2.19% of
total CpG sites) were excluded from further analyses. The methylation level of each
CpG site was represented by b values which ranged from 0 (unmethylated) to 1
(fully methylated).
A total of 193,531 genomic ‘‘segments’’ were deﬁned by their location against a
transcription start site (TSS) [TSS1500 (regions between 200 bp upstream and
1500 bp upstream from TSS), TSS200 (200 bp upstream region from TSS), 50-UTR,
1st exon, gene body, 30-UTR, and intergenic regions] and their relative location
against a CGI (N Shelf, N Shore, CGI, S Shore, S Shelf, and non-CGI). A genomic seg-
ment >500 bp was further divided into genomic ‘‘blocks’’. A genomic block was de-
ﬁned as a 500-bp region from an initial CpG site (probe), and the next genomic
block started from the next CpG site (Supplementary Fig. 1). A genomic segment
6500 bp was counted as one genomic block. A total of 282,805 genomic blocks were
produced, and 276,456 genomic blocks on autosomes were analyzed to enable com-
parison between males and females. A DNA methylation level of a genomic block
was evaluated using the average of b value of the CpG sites within the block. A
genomic block was considered as methylated when its b value was 0.4 or more,
and as unmethylated when its b value was 0.2 or less.
2.3. Analysis of sequence variations
A library DNA containing 226 amplicons of 55 cancer-related genes was pre-
pared from a sample by multiplex PCR using 50 ng of genomic DNA and an Ion Amp-
liSeq Cancer Panel Kit (Life Technologies) with 36 customized primers
(Supplementary Table 2). The 226 amplicons covered the vast majority of sampleswith mutations reported (91.9% or more) for 15 oncogenes and the TP53 tumor-sup-
pressor gene (83.1%), and variable fractions of samples with mutations reported
(3.3–88.5%) for 39 genes (Supplementary Table 3). Then, the entire library DNA
was uniquely barcoded by using an Ion Xpress Barcode Adaptors 1-16 Kit (Life
Technologies). The barcoded libraries from ﬁve to six samples were pooled, and
mixed with Ion Spheres for emulsion PCR using the Ion OneTouch System (Life
Technologies) with an Ion OneTouch Template Kit (Life Technologies). From the
product of emulsion PCR, the complexes of Ion Spheres with ampliﬁed DNA were
enriched by using Ion OneTouch ES (Life Technologies) and were loaded onto an
Ion 316 chip (Life Technologies). Sequencing was performed by using Ion PGM Se-
quencer (Life Technologies) with an Ion Sequencing Kit (Life Technologies). Ob-
tained sequences were mapped onto the human reference genome hg19, and
sequence variations with frequencies of 10% or more were identiﬁed by using
CLC Genomics Workbench 5.1 (CLC bio, Aarhus, Denmark). Common SNPs were ex-
cluded from further analysis. Reading depths of individual regions analyzed are
shown in Supplementary Table 4.
2.4. Dideoxy sequencing
A region containing a sequence variation identiﬁed was ampliﬁed using 20 ng of
genomic DNA with primers listed in Supplementary Table 5. The PCR product was
puriﬁed by a DNA Clean and Concentrator-5 Kit (Zymo Research, Irvine, CA), and
directly cycle-sequenced by using a DYEnamic ET Terminator Cycle Sequencing
kit (GE Healthcare, Buckinghamshire, UK) and an ABI PRISM 310 automated DNA
sequencer (PE Biosystems).
2.5. Analysis of gene expression by GeneChip oligonucleotide microarray
Gene expression levels in normal gastric mucosae were analyzed by using the
GeneChip Human Genome U133 Plus 2.0 microarray (Affymetrix, Santa Clara, CA)
as described [40]. Genes with signal intensities of 250 or more were deﬁned as ex-
pressed genes.
2.6. Cluster analysis
Unsupervised hierarchical clustering analysis was performed by using R 2.15 [R
Core Team (2012) R: A language and environment for statistical computing. R Foun-
dation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://
www.R-project.org/] with the Heatplus package [Alexander Ploner (2011) Heat-
plus: Heatmaps with row and/or column covariates and colored clusters, R package
version 2.2.0.] from Bioconductor [41]. The Euclidean distance was used as distance
function both for samples and genes. Due to the limitation in the calculation algo-
rithm for the hierarchical clustering, 25,000 elements or less were analyzed.
2.7. Survival curve
Survival curves were analyzed using the Kaplan-Meier method, and the Kaplan-
Meier curve was drawn by using SPSS 13.0J (SPSS, Chicago, IL, USA).
2.8. Statistical analysis
The association between the CIMP and oncogene mutations, and that between
genes aberrantly methylated in GCs and target genes of polycomb repressive com-
plex (PRC) 2 in human embryonic stem (ES) cells were tested by the chi-square test.
The differences in the survival rates among groups were evaluated using the Man-
tel-Cox test.
3. Results
3.1. Comprehensive analysis of DNA methylation proﬁles
DNA methylation levels were compared between GCs and nor-
mal gastric mucosae. First, using all the 276,456 genomic blocks,
some GCs, such as S24TP, S33TP, and S37TP, had a larger fraction
of aberrantly methylated blocks than other GCs, such as S2TP,
S4TP, and S15TP (Fig. 1 and Supplementary Fig. 2). Second, the
analysis was conducted using 6877 TSS200 CGIs unmethylated in
normal gastric mucosae (genes unmethylated in normal gastric
mucosae) because a TSS200 CGI is known to play a critical role in
methylation-silencing [42]. The number of aberrantly methylated
genes ranged from three to 1211. Third, we focused on TSS200 CGIs
of genes with positive expression in normal cells but aberrantly
methylated in cancer cells because this group of genes is known
to frequently contain driver genes in carcinogenesis [43]. Using
263 TSS200 CGIs whose downstream genes were expressed in
Fig. 1. Comprehensive analysis of DNA methylation proﬁles in GCs. DNA methylation levels were compared between GCs and normal gastric mucosae for the 276,456
genomic blocks. S24TP, S33TP, and S37TP (lower three panels) had a larger fraction of aberrantly methylated genes (yellow-colored areas) than S2TP, S4TP, and S15TP (upper
three panels). The vertical and horizontal axes indicate the methylation levels in GCs and the mean methylation levels of three normal mucosae, respectively.
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GCs (methylation-silenced genes), the number ranged from 0 to
166. These results showed that the number of aberrantly methyl-
ated genes was highly variable among individual GCs.
3.2. Extensive mutation analysis of the 55 cancer-related genes
Mutations were analyzed for the 55 cancer-related genes.
Among the 30 GCs, 22 GCs had 30 sequence variations of at least
one gene (Table 1 and Supplementary Table 6), and all the 30 se-
quence variations were conﬁrmed by dideoxy sequencing (Supple-
mentary Fig. 3). The conﬁrmed sequence variations were analyzed
whether or not they were somatic mutations using corresponding
non-cancerous tissues. The 24 of the 30 sequence variations were
shown to be somatic mutations (Fig. 2 and Table 1), and were
present in 19 GCs. Among the 24 mutations, 22 were missense
mutations, and two were nonsense mutations. Three GCs (S5TP,
S13TP, and S33TP) had two or more mutations of different genes.
Four oncogenes, CTNNB1, ERBB2, KRAS, and PIK3CA, and four
tumor-suppressor genes, CDH1, MLH1, SMARCB1, and TP53, were
mutated. TP53 was most frequently mutated (43%, 13 of the 30
GCs), and CTNNB1, ERBB2, KRAS, and PIK3CA were mutated in two
GCs. These results showed that 63% of GCs (19 out of the 30 GCs)
had at least one somatic mutation of known cancer-related genes.
3.3. The association between the CIMP and mutations of oncogenes
Unsupervised hierarchical clustering analysis was conducted
ﬁrst using DNA methylation proﬁles of 25,000 genomic blocks ran-
domly selected from all the 276,456 genomic blocks. However, the
numbers of aberrantly methylated genes in GCs of different clus-
ters did not appear to be different (Supplementary Fig. 4). Then,
we again conducted unsupervised hierarchical clustering using
DNA methylation proﬁles of CGIs, namely 25,000 genomic blocks
randomly selected from 59,992 blocks with CGIs (Fig. 3A). This
time, clusters I (n = 3) and IIb (n = 13) contained GCs with a larger
number of aberrantly methylated genes than GCs in cluster IIa
(n = 14). Among the 16 GCs in clusters I and IIb, seven GCs were
shown to have mutations of oncogenes, CTNNB1, ERBB2, KRAS,
and PIK3CA.Thirdly, using DNA methylation proﬁles of 6877 genes unme-
thylated in normal gastric mucosae, two major clusters were ob-
served (Fig. 3B). Cluster III (n = 11) contained GCs with a
relatively large number of aberrantly methylated genes, and seven
of the 11 GCs of this cluster were shown to have mutations of
oncogenes, CTNNB1, ERBB2, KRAS, and PIK3CA. In contrast, cluster
IV (n = 19) contained GCs with a relatively small number of aber-
rantly methylated genes, and none of the 19 GCs in this cluster
had mutations of oncogenes. The difference was markedly statisti-
cally signiﬁcant (P = 7.15  105), and GCs in cluster III and IV were
considered to be the CIMP-positive [CIMP(+)] and the CIMP-negative
[CIMP()], respectively.
Fourth, using DNA methylation proﬁles of the 263 methylation-
silenced genes, three major clusters were produced (Fig. 3C). Clus-
ter V (n = 3) contained GCs with the largest number of aberrantly
methylated genes, and two of the three GCs were shown to have
mutations of PIK3CA. Cluster VIa (n = 8) contained GCs with a rela-
tively larger number of aberrantly methylated genes than GCs in
cluster VIb (n = 19). Five of the eight GCs in this cluster were shown
to have mutations of oncogenes, CTNNB1, ERBB2, KRAS. Clusters VIb
contained the same sets of GCs as cluster IV, the previous cluster-
ing, except for one. These results showed that the CIMP(+) GCs
were associated with mutations of oncogenes, such as CTNNB1,
ERBB2, KRAS and PIK3CA, in GCs.3.4. Possible association between the CIMP and good prognosis
To analyze an association between the CIMP status and progno-
sis of patients, Kaplan-Meier curves were drawn using overall sur-
vival (OS). Using the CIMP status based on the DNA methylation of
the 6877 genes unmethylated in normal gastric mucosae, it was
revealed that the prognosis of the CIMP(+) patients (Cluster III in
Fig. 3B) tended to be better than that of the CIMP() patients (Clus-
ter IV in Fig. 3B) (P = 0.285; Fig. 4). Also, using the CIMP status
based on the methylation of the 263 methylation-silenced genes,
the prognosis of the CIMP(+) patients (Cluster V and VIa in
Fig. 3C) tended to be better than that of the CIMP() patients
(Cluster VIb in Fig. 3C) (P = 0.285; Supplementary Fig. 5). These re-
sults suggested that the CIMP(+) status is possibly associated with
good prognosis in GCs.
Table 1
List of somatic mutations identiﬁed in the 30 GCs.
Sample
#
Sample
name
Gene Coverage Variant
frequencies
Nucleotide
change
Amino acid
change
1 S1TP CDH1 339 10.3 c.1198G > A p.Asp400Asn
2 S2TP TP53 496 34.1 c.581T > G p.Leu194Arg
3 S4TP TP53 438 74.2 c.581T > G p.Leu194Arg
4 S5TP KRAS 1626 54.4 c.38G > A p.Gly13Asp
SMARCB1 50 56 c.1130G > A p.Arg377His
5 S6TP TP53 2077 24.7 c.820G > C p.Val274Leu
6 S9TP No mutation
7 S11TP TP53 10,211 53.4 c.844C > T p.Arg282Trp
8 S12TP ERBB2 24,516 63.8 c.2264T > C p.Leu755Ser
9 S13TP TP53 70 15.7 c.478A > G p.Met160Val
ERBB2 482 23.9 c.2264T > C p.Leu755Ser
10 S14TP No mutation
11 S15TP TP53 534 40.3 c.743G > A p.Arg248Gln
12 S16TP TP53 453 36.2 c.660T > G p.Tyr220Ter
13 S17TP No mutation
14 S18TP TP53 1946 26.5 c.844C > T p.Arg282Trp
15 S19TP No mutation
16 S20TP No mutation
17 S22TP No mutation
18 S23TP TP53 565 67.8 c.537T > A p.His179Gln
19 S24TP No mutation
20 S32TP No mutation
21 S33TP MLH1 4092 45.4 c.1744C > G p.Leu582Val
CTNNB1 11,994 20.5 c.101G > A p.Gly34Glu
PIK3CA 276 49.3 c.1633G > A p.Glu545Lys
TP53 1142 34.9 c.524G > A p.Arg175His
22 S34TP TP53 551 28.3 c.641A > G p.His214Arg
23 S35TP KRAS 770 41.3 c.35G > T p.Gly12Val
24 S36TP TP53 1142 34.9 c.524G > A p.Arg175His
25 S37TP PIK3CA 59 15.3 c.1624G > A p.Glu542Lys
26 S40TP No mutation
27 S42TP No mutation
28 S43TP TP53 239 74.9 c.1024C > T p.Arg342Ter
29 S45TP No mutation
30 S47TP CTNNB1 4591 33.7 c.121A > G p.Thr41Ala
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genes targeted by PRC2 in ES cells
The fraction of genes targeted by PRC2 in ES cells was analyzed
in the genes aberrantly methylated in GCs and those unmethylated
in GCs because genes methylated in GCs were reported to be asso-
ciated with PRC2 target genes [33]. Using the information on the
PRC2 target genes in human ES cells [44,45], it was shown that
the genes aberrantly methylated in GCs consisted of a larger frac-
tion of PRC2 target genes than those unmethylated in GCs
(P = 6.64  1079) (Supplementary Fig. 6). These results conﬁrmed
that genes aberrantly methylated in GCs were associated with
genes targeted by PRC2 in ES cells.
4. Discussion
In this study, we conducted comprehensive DNA methylation
analysis and extensive mutation analysis of 30 GCs, and showed
(1) that the number of aberrantly methylated genes was highly
variable among the 30 GCs, (2) that 19 of the 30 GCs had 24 so-
matic mutations of 8 different genes (CDH1, CTNNB1, ERBB2, KRAS,
MLH1, PIK3CA, SMARCB1, and TP53), and (3) that the CIMP was
associated with mutations of oncogenes, including ERBB2, CTNNB1,
KRAS, and PIK3CA, in GCs. This is one of the ﬁrst studies in which
both genetic and epigenetic alterations were extensively analyzed
in the same set of samples, and the association between the CIMP
and mutations of oncogenes in GCs was revealed here for the ﬁrst
time.
A similar association has been known also in colorectal can-
cers, but the mechanisms for this association are still unclear.As a possible mechanism, it has been proposed (1) that cancers
with the CIMP can escape senescence caused by BRAF mutation
owing to silencing of regulators of senescence by BRAF muta-
tion, such as IGFBP7 [46,47], and (2) that overexpression of
the BRAF mutant can induce aberrant methylation at various
genes, such as MLH1 [48]. Similar possibilities can be hypothe-
sized in GCs. As a mechanism for methylation induction by
oncogenic mutation, if this applies to GCs, there is a possibility
that oncogenic mutations displace factors involved in the sus-
ceptibility to methylation induction, such as RNA polymerase
II [40,49–53].
Somatic mutations of four tumor-suppressor genes, CDH1,
MLH1, SMARCB1, and TP53, and four oncogenes, CTNNB1, ERBB2,
KRAS, and PIK3CA, were identiﬁed. Among these mutated genes,
TP53 (32%), CDH1 (20%), PIK3CA (10%), CTNNB1 (9%), KRAS (7%),
and ERBB2 (2%) are listed in the top 15 mutated genes in GCs
in the Catalogue Of Somatic Mutations In Cancer (COSMIC) data-
base. In contrast, mutations of SMARCB1 have not been identiﬁed
in GCs, even by whole exome sequencing [11,12], but were
identiﬁed for the ﬁrst time in this study, showing the usefulness
of extensive mutation analysis of known cancer-related genes.
SMARCB1 encodes a component of chromatin remodeling
complex, SWI/SNF, and is mutated in malignant rhabdoid tumors
[54]. In GCs, the defects of components of SWI/SNF, such as muta-
tion of ARID1A [11,12] and loss of BRM expression, are known
[55]. Therefore, it is considered that the dysfunction of chromatin
remodeling activity plays an important role in gastric
carcinogenesis.
The selection of genomic blocks heavily inﬂuenced the results of
unsupervised hierarchical clustering analysis. The association be-
tween the CIMP and mutations of oncogenes was clearly observed
using DNA methylation proﬁles of the selected 6877 and 263
blocks, and some association was observed using the methylation
proﬁles of the 25,000 blocks with CGIs. In contrast, no association
was observed using the 25,000 blocks randomly selected from all
the blocks. Therefore, it is considered that the selection of biologi-
cally important probes (or genes) is required to extract meaningful
information from the huge amount of data obtained by compre-
hensive DNA methylation analysis.
We previously found that the CIMP statuses in GCs were not
associated with DNA methylation statuses in background non-
cancerous mucosae, contrary to expectations [30]. The presence
of the CIMP(+) GCs suggested that CGIs methylated in GCs are
composed of those methylated as a result of the CIMP and those
methylated in background non-cancerous mucosae.
The genes aberrantly methylated in GCs here were associated
with genes targeted by PRC2 in ES cells, conﬁrming previous re-
ports. It has been known that genes methylated in other types
of cancers are associated with genes targeted by PRC2 in ES
cells [49,50,53] or normal cells [40,50–52]. A recent comprehen-
sive analysis in GCs also revealed that genes methylated in GCs
were associated with genes targeted by PRC2 in ES cells [33].
EZH2, a component of PRC2, and CBX7, a component of PRC1,
are known to interact with DNA methyltransferases [56,57],
and these interactions seem to be a possible mechanism of
the high frequency of DNA methylation of the genes targeted
by PRC2.
The prognosis of the CIMP(+) patients tended to be better than
that of the CIMP() patients. The association between the CIMP
and prognosis is highly dependent upon cancer types. For example,
the CIMP is associated with poor prognosis in colorectal cancers
[28], lung cancers [29], and neuroblastoma [27]. In GCs, some
studies showed association with good prognosis [30,31], and
others showed that with poor prognosis [32,33]. The reason why
the CIMP in GCs was associated with good prognosis in some
studies is unknown, but it might be possible that genes involved
Fig. 2. Results of extensive mutation analysis of the 30 GCs. Mutations of the 55 known cancer-related genes were analyzed by Ion Torrent PGM sequencer. Among the 30
GCs, 19 had 24 somatic mutations of 8 different genes. TP53 was mutated in 13 GCs (43%, 13 of the 30 GCs), and CTNNB1, ERBB2, KRAS, and PIK3CA were mutated in two GCs,
respectively. The presence of a somatic mutation is shown by a ﬁlled square.
J.G. Kim et al. / Cancer Letters 330 (2013) 33–40 37in tumor progression are silenced by aberrant DNA methylation in
GCs with the CIMP.
In conclusion, integrated analysis of genetic and epigenetic
alterations revealed that the CIMP was associated with muta-
tions of oncogenes, including ERBB2, CTNNB1, KRAS and PIK3CA,
in GCs.Acknowledgements
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Fig. 3. The association between the DNA methylation proﬁle and gene mutations. (A) Unsupervised hierarchical clustering analysis using DNA methylation proﬁles of 25,000
genomic blocks with CGIs. Clusters I (n = 3) and IIb (n = 13) contained GCs with a relatively large number of aberrantly methylated genes, and seven of the 16 GCs were shown
to have mutations of oncogenes. (B) Unsupervised hierarchical clustering analysis using DNA methylation proﬁles of the 6877 blocks (genes) unmethylated in normal gastric
mucosae. Cluster III (n = 11) contained GCs with a relatively large number of aberrantly methylated genes, and seven of the 11 GCs were shown to have mutations of
oncogenes. (C) Unsupervised hierarchical clustering analysis using DNA methylation proﬁles of the 263 methylation-silenced genes. Cluster V (n = 3) contained GCs with the
largest number of aberrantly methylated genes, and two of the three were shown to have PIK3CA mutations.
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Fig. 4. The possible association between the CIMP and good prognosis. Kaplan-
Meier curves were drawn using overall survival (OS). The CIMP status was
determined based on the DNA methylation proﬁle of the 6877 genes unmethylated
in normal gastric mucosae. The prognosis of the CIMP(+) patients (n = 11) tended to
be better than that of the CIMP() patients (n = 19) (P = 0.285).
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Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.canlet.2012.11.
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